Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessme

1. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

2. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 • Date: 28 February 2012 • Pages: 80 • Summary “Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Chronic Heart Failure Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Heart Failure Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chronic Heart Failure Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope The report provides information on the key drivers and challenges of the Chronic Heart Failure Therapeutics market. Its scope includes -  - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Heart Failure Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.  - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Chronic Heart Failure Therapeutics market.  - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.  - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Heart Failure Therapeutics market. - Analysis of key recent licensing and partnership agreements in Chronic Heart Failure Therapeutics market

3. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Reasons to buy The report will enhance your decision making capability. It will allow you to -  - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.  - Develop business strategies by understanding the trends shaping and driving the global Chronic Heart Failure Therapeutics market.  - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Heart Failure Therapeutics market in future.  - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.  - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.  - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.  - What’s the next big thing in the global Chronic Heart Failure Therapeutics market landscape? – Identify, understand and capitalize.

4. 1.1 List of Tables 51.2 List of Figures 62 Chronic Heart Failure Therapeutics - Introduction 72.1 Overview 72.2 Etiology 82.3 Pathophysiology 102.4 Epidemiology and Prognosis 122.5 Symptoms 132.6 Diagnosis 132.7 Treatment and Management Pattern 182.7.1 Pharmacological Therapies 182.7.2 Treatment Goals for Patients with Heart Failure 182.8 GlobalData Report Guidance 203 Chronic Heart Failure Therapeutics - Market Characterization 213.1 Chronic Heart Failure Therapeutics Market Size (2006-2011) - Global 213.2 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Global 223.3 Chronic Heart Failure Therapeutics Market Size (2006-2011) - The US 233.4 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - The US 243.5 Chronic Heart Failure Therapeutics Market (2006-2011) - France 253.6 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - France 263.7 Chronic Heart Failure Therapeutics Market (2006-2011) - Germany 273.8 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Germany 283.9 Chronic Heart Failure Therapeutics Market (2006-2011) - Italy 293.10 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Italy 303.11 Chronic Heart Failure Therapeutics Market (2006-2011) - Spain 313.12 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Spain 323.13 Chronic Heart Failure Therapeutics Market (2006-2011) - The UK 333.14 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - The UK 343.15 Chronic Heart Failure Therapeutics Market (2006-2011) - Japan 353.16 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Japan 363.17 Drivers and Barriers for the Chronic Heart Failure Therapeutics Market 373.17.1 Drivers for the Chronic Heart Failure Therapeutics Market 373.17.2 Barriers for the Chronic Heart Failure Therapeutics Market 373.18 Opportunity and Unmet Need Analysis 383.19 Key Takeaway 39

5. 4 Chronic Heart Failure Therapeutics - Competitive Assessment 404.1 Overview 404.2 Strategic Competitor Assessment 404.3 Product Profile for the Major Marketed Products in the Chronic Heart Failure Therapeutics Market 414.3.1 Beta-adrenergic Receptor Blockers (Beta Blockers) 414.3.2 Coreg (carvedilol) 414.3.3 Altace (ramipril) 424.3.4 Diovan (valsartan) 434.4 Key Takeaway 445 Chronic Heart Failure Therapeutics - Pipeline Assessment 455.1 Overview 455.2 Strategic Pipeline Assessment 455.3 Chronic Heart Failure Therapeutics Pipeline - Pipeline by Phase of Development 455.3.1 Chronic Heart Failure Therapeutics - Phase III Pipeline 465.3.2 Chronic Heart Failure Therapeutics - Phase II Pipeline 465.3.3 Chronic Heart Failure Therapeutics - Phase I Pipeline 475.3.4 Chronic Heart Failure Therapeutics - Preclinical Pipeline 475.3.5 Chronic Heart Failure Therapeutics - Discovery Pipeline 475.4 Chronic Heart Failure Therapeutics Market - Clinical Pipeline by Mechanism of Action 485.5 Technology Trends Analytical Framework 495.6 Chronic Heart Failure Therapeutics - Promising Drugs Under Clinical Development 505.7 Molecule Profile for Phase III Drugs Under Clinical Development 515.7.1 LCZ696 515.7.2 Lixivaptan 515.7.3 Tekturna/Rasilez (aliskiren) 525.7.4 Aranesp 525.8 Key Takeaway 536 Chronic Heart Failure Therapeutics - Clinical Trials Mapping 546.1 Clinical Trials by Region/Country (The US, EU5, and Japan) 546.2 Clinical Trials by Phase 556.3 Clinical Trials by Trial Status 566.4 Clinical Trials by Overall Sponsors 576.5 Prominent Sponsors 586.6 Key Companies Participating in Therapeutics Clinical Trials 59

6. 7 Chronic Heart Failure Therapeutics - Strategic Assessment 607.1 Key Events Impacting the Future Market 607.2 Chronic Heart Failure Therapeutics: Implications for Future Market Competition 618 Chronic Heart Failure Therapeutics - Future Players 628.1 Introduction 628.2 Company Profiles 638.2.1 Novartis AG. 638.2.2 Amgen Inc. 658.2.3 Cardiokine, Inc 668.2.4 Bayer AG. 678.2.5 Nile Therapeutics, Inc. 688.2.6 Cardioxyl Pharmaceuticals, Inc 698.2.7 Cytokinetics, Inc 708.2.8 GlaxoSmithKline plc 718.2.9 Trevena, Inc. 729 Chronic Heart Failure Therapeutics - Licensing and Partnership Deals 7310 Chronic Heart Failure Therapeutics - Appendix 7410.1 Market Definitions 7410.2 Acronyms 7410.3 Research Methodology 7510.3.1 Coverage 7610.3.2 Secondary Research 7610.3.3 Forecasting 7610.3.4 Primary Research 7810.3.5 Expert Panel Validation 7910.4 Contact Us 7910.5 Disclaimer 7910.6 Bibliography 80

7. For more information, please visit: • http://www.aarkstore.com/reports/Chronic-Heart-Failure-CHF-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019-222643.htmlOr email us at contact@aarkstore.com or call +919272852585 • Related Reports • Vemurafenib - Comprehensive patent searchColesevelam - Comprehensive patent searchRifaximin - Comprehensive patent searchNevirapine - Comprehensive patent searchLiraglutide - Comprehensive patent searchVilazodone - Comprehensive patent searchHexylaminolevulinic Acid - Comprehensive patent searchTreprostinil - Comprehensive patent searchPatient Adherence, Communication and Engagement (PACE) - Increased Investment and Adoption of New Digital Tools Enable Key Stakeholder Collaborations and Encourage ComplianceExpress Scripts, Inc.: Pharmaceuticals and Healthcare Company Profile, SWOT and Financial Report

8. Contact Us Aarkstore Enterprise Tel : +912227453309 Mobile No:+08149852585 Email : contact@aarkstore.com Website : http://www.aarkstore.com Blog: http://www.emarketreports.com http://teju-aarkstoreenterprise.blogspot.in Follow us on twitter: http://twitter.com/aarkstoredotcom http://in.linkedin.com/in/aarkstore http://www.facebook.com/aarkstoreenterprise